When to Use Amiodarone vs. Adenosine: Key Differences

Adenosine and amiodarone treat different kinds of dangerous heart rhythms, and choosing between them depends almost entirely on the type of arrhythmia you’re dealing with. Adenosine is the go-to drug for a fast but regular rhythm called paroxysmal supraventricular tachycardia (PSVT), where it works within seconds by briefly blocking electrical signals through the AV node. Amiodarone handles a broader and often more dangerous set of rhythm problems, particularly ventricular tachycardia and ventricular fibrillation, and it acts over hours rather than seconds. The two drugs are rarely interchangeable, but understanding how they differ in mechanism, timing, side effects, and clinical context helps make sense of why clinicians reach for one over the other.

The Core Distinction in What They Treat

Adenosine’s primary role is treating PSVT, a rhythm disturbance that originates above the heart’s ventricles and typically involves a short-circuit loop through the AV node. When adenosine is given as a rapid intravenous push, it temporarily halts conduction through that node, breaking the loop. Intravenous adenosine is the recommended first-line treatment for PSVT after physical maneuvers like bearing down or applying cold water to the face have failed.¹ A prehospital study found that adding adenosine to the treatment protocol raised conversion rates for PSVT from about 32% to 59%.²

Amiodarone covers different ground. It was approved in the United States in 1995 specifically for malignant and treatment-resistant ventricular arrhythmias, with suppression rates between 63% and 91% in clinical experience.³ It also works against supraventricular tachycardias, suppressing recurrences in roughly 80% or more of patients in that category, though it is not typically the first drug tried for those rhythms.⁴ Its real niche is in life-threatening ventricular rhythms, cardiac arrest protocols, and situations where other antiarrhythmic drugs have failed. In advanced cardiac life support algorithms, amiodarone is recommended for shock-resistant ventricular fibrillation and pulseless ventricular tachycardia, while adenosine appears in the stable narrow-complex tachycardia pathway.

How Each Drug Works

Adenosine is an endogenous molecule, meaning your body already produces it. When injected, it activates a specific receptor (A1-type) on cells in the AV node, which slows and briefly blocks electrical conduction through that structure.⁵ At the cellular level, adenosine prolongs the time AV node cells need to recover between beats and raises the threshold for those cells to fire, which is why the heart momentarily pauses and then, ideally, resets into a normal rhythm.⁶ The effect is extremely short-lived because enzymes in the blood break adenosine down within seconds. That ultra-short half-life is both its strength and its limitation: it works fast and wears off fast, which makes it safe for a quick diagnostic or therapeutic reset but useless for rhythms that need sustained control.

Amiodarone works through a completely different and far more complex set of actions. It blocks several types of potassium channels in heart cells, which delays the electrical recovery (repolarization) phase and lengthens the time between beats. Research on one key potassium channel (HERG) showed amiodarone could reduce the current through those channels by over 60%.⁷ It also targets another type of potassium “leak” channel in the heart, contributing further to prolonged repolarization and action potential duration.⁸ Beyond potassium channels, amiodarone also affects sodium channels, calcium channels, and certain receptors involved in heart rate control. This multi-channel activity is part of why amiodarone works against such a wide range of arrhythmias, but it’s also why the drug carries a heavier burden of side effects.

Speed, Duration, and How They’re Given

Adenosine must be given as a fast intravenous push, followed immediately by a saline flush. Speed matters because the drug is cleared from the bloodstream so rapidly that a slow injection may never reach the heart in high enough concentration to work. The standard initial dose in adults is 6 mg, followed by 12 mg if the first dose doesn’t convert the rhythm, with a possible second 12 mg dose after that. The entire therapeutic episode, from injection to rhythm conversion or failure, typically unfolds within 30 seconds to a minute. The fleeting nature of its effect means that even if an unwanted side effect occurs, it almost always resolves on its own within moments.

Amiodarone is administered differently in almost every respect. In emergency settings, a loading dose is given intravenously over 10 minutes (typically 150 mg for adults), followed by a slow continuous infusion over hours. In cardiac arrest, it can be pushed more rapidly. The drug’s onset of action is slower, with noticeable effects on heart rate appearing over the first hour or so. In a study of pediatric cardiac surgical patients, heart rate dropped meaningfully within one hour of starting the infusion, from an average of about 195 beats per minute to roughly 158, while blood pressure held steady or slightly improved.⁹ Amiodarone has an extraordinarily long half-life, on the order of weeks to months with chronic oral use, because it accumulates in fat tissue throughout the body. Even intravenous courses have effects that persist well beyond the infusion itself.

When Adenosine Fails and Amiodarone Steps In

In practice, clinicians sometimes encounter scenarios where adenosine successfully converts a rhythm temporarily but the arrhythmia returns. A study of neonates and small infants with life-threatening supraventricular tachycardia illustrates this pattern: rapid adenosine injection converted the rhythm to normal sinus in some patients, but recurrent tachycardia then required switching to intravenous amiodarone for sustained control. Other infants in the same study, whose arrhythmia only temporarily responded to adenosine, were started on amiodarone from the outset.¹⁰ This reflects the general clinical principle: adenosine is first-line for acute termination of PSVT, but when the arrhythmia keeps coming back or doesn’t respond, amiodarone (or a similar longer-acting agent) becomes necessary.

A systematic review of pediatric supraventricular tachycardia confirmed this layered approach. Adenosine, with its short half-life, remains the first-line option for acute management, particularly when the electrocardiogram tracing is uncertain and the clinician wants a quick diagnostic and therapeutic test. Amiodarone showed better results when administered within 48 hours of diagnosis for sustained rhythm control and is preferred for certain specific arrhythmia subtypes, including junctional ectopic tachycardia, where pre-operative preventive dosing can lower the incidence.¹¹

Side Effects and Toxicity Profiles

Because adenosine is cleared in seconds, its side effects are brief and usually tolerable, though they can feel alarming. Patients often report a sensation of chest tightness, flushing, shortness of breath, or a momentary feeling that the heart has stopped. There is also a known association with bronchospasm, though some researchers suggest this may reflect irritant-induced breathlessness rather than true airway obstruction in many cases.¹² Despite these transient effects, adenosine’s safety profile is one of its most valued features. In animal studies, adenosine causes dose-related drops in both heart rate and blood pressure, similar to intravenous ATP.¹³ In clinical practice, the rapid clearance means these hemodynamic effects rarely become dangerous.

Amiodarone’s side-effect profile is another matter entirely. Short-term intravenous use can cause hypotension, particularly with faster infusion rates, and phlebitis at the IV site. But the real toxicity concerns emerge with longer-term use. Amiodarone is known for causing damage to the liver, lungs, thyroid, and eyes.¹⁴ Liver effects range from mild, symptom-free rises in liver enzymes to outright hepatic failure requiring transplantation. Pulmonary toxicity can manifest as inflammation and fibrosis in the lungs. Thyroid problems are especially common: an estimated 15% to 20% of patients on amiodarone develop some form of thyroid dysfunction, which can swing in either direction, toward an underactive or overactive thyroid.¹⁵ This happens partly because amiodarone is loaded with iodine, roughly 37% by weight, which floods the thyroid with far more iodine than it normally processes. Patients on long-term amiodarone need regular monitoring of thyroid, liver, and lung function, along with eye exams to watch for corneal deposits or optic nerve damage.

Drug Interactions

Adenosine has relatively few drug interactions, but two deserve attention. Caffeine and theophylline block the same A1 receptors adenosine acts on, which can reduce its effectiveness. Patients who have consumed large amounts of caffeine may need higher doses, and those on theophylline may not respond well to adenosine at all. On the other side, dipyridamole, a drug that inhibits adenosine breakdown, can dramatically amplify adenosine’s effects, meaning patients on dipyridamole typically require a much lower starting dose.

Amiodarone is far more interactive. It powerfully inhibits several liver enzymes responsible for metabolizing other drugs, which means it can cause the blood levels of those drugs to climb to dangerous concentrations. The interactions with digoxin and warfarin are particularly important: when amiodarone is added to either of these, their doses should generally be cut in half right away to avoid toxicity.¹⁶ Amiodarone also impairs the metabolism of theophylline and interacts with a long list of other medications. Because amiodarone persists in the body for weeks after the last dose, these interactions can continue well after the drug has been stopped, which adds a layer of complexity that adenosine, with its seconds-long life span, simply doesn’t have.

Pregnancy and Reproductive Safety

Arrhythmias can occur or worsen during pregnancy due to the increased blood volume and hormonal shifts that come with carrying a child. When PSVT strikes during pregnancy and physical maneuvers don’t work, adenosine is recommended as the first-line drug during the second and third trimesters. The evidence base in the first trimester is thinner, with less data available to guide treatment.¹⁷ Adenosine’s extremely short duration of action works in its favor here: the drug is cleared before it can meaningfully cross the placenta or accumulate in fetal tissue.

Amiodarone carries substantially more risk in pregnancy. Its iodine content can cross the placenta and affect fetal thyroid development, potentially causing neonatal hypothyroidism or goiter. Because of this, amiodarone is generally reserved for pregnant patients only when life-threatening arrhythmias have not responded to safer alternatives. When it must be used, close fetal thyroid monitoring is recommended.

The Transplanted Heart

Heart transplant recipients represent a uniquely important special case for adenosine use. The transplanted heart has had its nerve connections severed (it’s denervated), which changes how it responds to adenosine. Research has shown that the denervated donor heart is three to six times more sensitive to adenosine’s slowing effects on the sinus node and AV node compared to a normally innervated heart.¹⁸ The duration of the slowing effect also lasted three to five times longer in the denervated heart. This means standard adenosine doses can cause prolonged and potentially dangerous pauses in transplant patients. If adenosine is used at all in this population, dramatically reduced doses are needed, and many clinicians prefer alternative approaches altogether.

Availability and Patterns of Use

Amiodarone is widely available in most healthcare settings worldwide, partly because it has been in use since the 1960s and is produced by many manufacturers. Adenosine, despite being a first-line drug in international guidelines, faces surprisingly variable availability. A multi-province survey of Chinese emergency departments found that only about 35% of physicians reported using adenosine, compared with nearly 64% who used amiodarone. Only about 54% of hospitals surveyed stocked adenosine, and just over 55% of emergency departments maintained consistent supplies.¹⁹ This gap between guideline recommendations and real-world availability means amiodarone sometimes ends up being used for PSVT not because it’s the ideal first choice, but because it’s the drug that’s actually on the shelf.

In resource-limited or prehospital settings, the logistical constraints of adenosine administration also play a role. The drug requires a peripheral IV line close to the heart (ideally in the antecubital fossa or higher), a rapid push technique, and an immediate saline flush. Any delay in the flush can mean the drug breaks down before reaching the AV node. Amiodarone, given as a slower infusion, is less technique-dependent, though it requires cardiac monitoring equipment and the ability to manage potential hypotension.

Diagnostic Value of Adenosine

Beyond its therapeutic role, adenosine serves a diagnostic function that amiodarone does not. When a patient presents with a fast, narrow-complex tachycardia and the exact rhythm isn’t clear on the ECG, a dose of adenosine can help unmask the underlying mechanism. By briefly blocking AV node conduction, adenosine can reveal atrial flutter waves, atrial tachycardia, or other rhythms that were hidden by the rapid ventricular rate. Even if the arrhythmia doesn’t terminate, the transient slowing gives clinicians a diagnostic window they wouldn’t otherwise have. This is one of the reasons a pediatric systematic review noted adenosine’s particular value when the electrocardiogram is uncertain.¹¹ Amiodarone, because it acts slowly and affects many channel types simultaneously, doesn’t offer this kind of clean diagnostic snapshot.

When Either Drug Could Apply

There is a gray zone where both drugs have some role, particularly in supraventricular tachycardias that are recurrent or resistant. Adenosine terminates most episodes of PSVT acutely, but it doesn’t prevent recurrence. A patient whose PSVT keeps coming back during a single hospital visit may need something longer-acting. Amiodarone can fill that role, though other options like beta-blockers or calcium channel blockers are often tried before escalating to amiodarone given its toxicity profile. In atrial fibrillation, adenosine has essentially no role (the arrhythmia doesn’t rely on the AV node circuit in the same way), while amiodarone is one of several drugs used for both rate control and rhythm conversion.

The clinical decision sometimes also hinges on blood pressure. A patient with stable blood pressure and a narrow-complex tachycardia gets adenosine. A patient with wide-complex tachycardia and a pulse gets amiodarone. A patient in cardiac arrest with ventricular fibrillation that persists after defibrillation gets amiodarone. Adenosine has essentially no role in cardiac arrest. The algorithms are intentionally designed so that these two drugs rarely compete for the same clinical slot; they complement each other across different tiers of arrhythmia severity.

Corneal Deposits and Other Unusual Amiodarone Effects

One amiodarone side effect that surprises many patients is the development of corneal microdeposits, tiny yellowish-brown whorls visible on eye examination. These appear in the vast majority of people taking amiodarone long-term and are usually painless, though some patients notice halos around lights, especially at night. More rarely, optic neuropathy can occur, which is a more serious concern because it can affect vision permanently. Case reports have documented multi-organ toxicity from amiodarone affecting the liver, lungs, thyroid, and eyes simultaneously in a single patient.¹⁴ The drug can also cause a distinctive bluish-gray skin discoloration with prolonged use, related to iodine and lipofuscin deposition in the skin. These cosmetic and ophthalmologic effects are among the reasons amiodarone is reserved for arrhythmias serious enough to justify the monitoring burden, rather than being prescribed casually. Adenosine, by contrast, leaves no trace in the body within a minute of injection.